Find Peptide Clinics
Clinic partner placement is available in select cities.View listing options

Popular Peptides: Five Carry an Approval Letter, the Rest Carry a Safety File

Find Peptide Clinics Editorial Desk

Popular peptides land on the same clinic menu and sit in two completely different parts of the federal record. Five of the compounds people search for most have an FDA approval letter with an application number and a date attached to it. The others have a public safety write-up, one paragraph long, in which FDA states what it does and does not know about the substance, and for two of the injectables on that list the write-up names heart-rate events and deaths.

The short answer: five popular peptides exist as FDA-approved drugs, and the rest are unapproved substances that FDA has already published a safety assessment about.

That gap takes about ten minutes to check, and it decides what a licensed pharmacy may lawfully hand to you.

Which popular peptides have an FDA approval letter

Five peptides from the standard internet list carry an approved drug product. Semaglutide holds two: Ozempic under NDA 209637, original approval December 5, 2017, and Wegovy under NDA 215256, June 4, 2021. Tirzepatide holds two more: Mounjaro under NDA 215866, May 13, 2022, and Zepbound under NDA 217806, November 8, 2023. Liraglutide appears as Saxenda, NDA 206321, December 23, 2014. Tesamorelin is Egrifta, BLA 022505, November 10, 2010. Bremelanotide is Vyleesi, NDA 210557, June 21, 2019. We pulled those numbers and dates from FDA’s own Drugs@FDA record for each application, not from a clinic page.

Read the approved labels, though, and the approvals turn out to be narrower than the marketing around them. Wegovy’s label, published June 30, 2026, covers three uses: reducing the risk of major adverse cardiovascular events in adults with established cardiovascular disease and obesity or overweight, long-term weight reduction, and noncirrhotic metabolic dysfunction-associated steatohepatitis with moderate to advanced fibrosis. Zepbound’s label, published September 2, 2026, covers two: weight reduction in adults with obesity or overweight plus a weight-related condition, and moderate to severe obstructive sleep apnea in adults with obesity.

Tesamorelin deserves a second reading. Egrifta WR is indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy, and its label carries a limitation of use in plain words: “EGRIFTA WR is not indicated for weight loss management as it has a weight neutral effect.” A peptide sold as a fat burner is, on its own approved label, weight neutral. Vyleesi has the same hard boundary. It treats acquired, generalized hypoactive sexual desire disorder in premenopausal women, and the label states that it “is not indicated for the treatment of HSDD in postmenopausal women or in men,” which puts use outside that population outside the approval.

The popular peptides with a safety file instead

BPC-157, TB-500, CJC-1295, ipamorelin, GHK-Cu, MOTS-c, AOD-9604, KPV, Semax, Epitalon and Melanotan II have no approved drug product in the United States. FDA keeps a page for that situation, titled Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks, with content current as of April 22, 2026. Each of those substances sits in a table headed “Bulk drug substances nominated but withdrawn,” and each carries a published paragraph describing what the agency found when it reviewed the nomination.

Compounded versions of these peptides are not the drugs in the approved trials, and they are not FDA-approved either. FDA’s own page on the 503A process spells out the standard a pharmacy has to meet to compound with a bulk substance at all: a United States Pharmacopeia or National Formulary monograph where one exists, or a component of an approved drug, or a place on FDA’s 503A bulks list, plus a valid certificate of analysis and a manufacturer registered with the agency.

What FDA wrote about each of them

CJC-1295 has the sharpest entry of the group. FDA’s safety write-up states: “FDA has identified serious adverse events associated with CJC-1295 including increased heart rate and systemic vasodilatory reaction. Available clinical data are limited.” That is the entire safety finding on the federal page, on a substance FDA lists as nominated but withdrawn. We walk through the label record on that one in more detail in CJC-1295 Peptide: FDA Recorded a Racing Heart.

Ipamorelin carries the heaviest sentence in the table: “A study published in literature identified serious adverse events including death when ipamorelin was administered intravenously for improving gastric motility.” FDA adds that it has not identified safety information for certain other injectable routes, so the agency lacks enough information to know whether the substance would cause harm by those routes.

BPC-157 gets a blunter entry. “FDA has identified no, or only limited, safety-related information for the proposed routes of administration. Therefore, the agency lacks sufficient information to know whether the drug would cause harm when administered to humans.” We keep the wider regulatory record for that compound on our BPC-157 status page, including the July 2026 advisory committee review covered in FDA Peptide Vote: What the Committee Did and Did Not Do.

MOTS-c and KPV share a sentence structure and a different fact. For MOTS-c, FDA wrote that it “has not identified any human exposure data on drug products containing MOTs-C administered via any route of administration,” and the same line appears for KPV. TB-500, the thymosin beta-4 fragment, has no human exposure data in the file either, and FDA adds that compounded versions may pose an immunogenicity risk through aggregation and peptide-related impurities. GHK-Cu gets a narrower warning limited to injectable routes: “There are limited data in humans to inform safety-related considerations.”

AOD-9604 reads differently, and the wording matters. FDA wrote that it “has also identified serious adverse events that may be associated with AOD-9604, though causality is not clear.” An event listed in a file is not a finding that the substance caused it. Melanotan II has the longest list of the set: “Published case reports discuss serious adverse events including melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome and priapism.”

Where popular peptides stand after the 2026 reviews

The regulatory position moved twice this year, and neither move was an approval. HHS released a draft policy on October 28, 2026 covering six peptides: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. The document records that each of the six sat in Category 2 from September 2023 until April 22, 2026, and that “neither the placement nor the removal changed their status under section 503A.” The Federal Register notice calls the document a draft and states that it is not binding on HHS or the public. We break the conditions down in Is BPC-157 legal now?.

FDA’s Pharmacy Compounding Advisory Committee met on July 23 and 24, 2026, and the agenda is worth reading for what the agency asked the committee to evaluate. The named uses were narrow: BPC-157 for ulcerative colitis, KPV for wound healing and inflammatory conditions, TB-500 for wound healing, MOTS-c for obesity and osteoporosis, Emideltide for opioid withdrawal, chronic insomnia and narcolepsy, Semax for cerebral ischemia, migraine and trigeminal neuralgia, and Epitalon for insomnia.

Two things follow from that list. The use FDA reviewed for BPC-157 was ulcerative colitis, not tendon repair, and the uses it reviewed for MOTS-c were obesity and osteoporosis, not energy or endurance. And a committee recommendation settles nothing on its own. FDA’s advisory committee page says the committees “make non-binding recommendations to the FDA, which generally follows the recommendations but is not legally bound to do so.” Any headline saying FDA legalized a peptide has to be read against that sentence.

How to check a popular peptide before you pay

Start with a number. An approved product has an NDA or BLA number and a label you can read on DailyMed, and the indication on that label is the only use FDA reviewed. An unapproved one has no such number, and the paperwork that matters is a certificate of analysis naming an FDA-registered manufacturer with its physical location, for a single-ingredient product.

Check the state side as well, because a federal enforcement position does not bind a state board of pharmacy or medicine, and those boards set rules for their own licensees. Our guide to state licensing and peptide legality covers that layer, and the compound status library holds the dated primary sources for each substance.

If you are choosing where to take questions, our clinic directory lists clinics by city. We do not label any listing licensed or verified: check each clinic’s license with the state board yourself, and ask the prescriber which product, from which manufacturer, at what strength, is being proposed.

Frequently asked questions

Which popular peptides are FDA approved?

Five peptides from the standard popular list carry an approved drug: semaglutide, tirzepatide, liraglutide, tesamorelin and bremelanotide. Their application numbers and original approval dates are listed in the section above, taken from FDA’s Drugs@FDA record.

Is BPC-157 FDA approved?

No. BPC-157 has no approved drug product in the United States. FDA’s safety page, dated April 22, 2026, states that the agency has identified no, or only limited, safety-related information for the proposed routes of administration.

What did FDA say about CJC-1295?

FDA’s safety write-up for CJC-1295 names serious adverse events including increased heart rate and a systemic vasodilatory reaction, and adds that available clinical data are limited. The same page carries the substance in its nominated but withdrawn table.

Did an FDA committee legalize any peptides in 2026?

No. The Pharmacy Compounding Advisory Committee met on July 23 and 24, 2026, to review seven substances for possible inclusion on the 503A bulks list, and FDA describes those recommendations as non-binding. HHS then released a draft enforcement discretion policy on October 28, 2026, which the Federal Register notice calls a draft that is not binding on HHS or the public.

Is tesamorelin a weight loss drug?

Not on its label. Egrifta WR is indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy, and the label states that it is not indicated for weight loss management because it has a weight neutral effect.

Are compounded peptides the same as the approved drugs?

No. Compounded products are not FDA-approved, they are not the products tested in the approval trials, and HHS states in that same policy that FDA does not review their safety, effectiveness or quality before they are marketed. A compounded peptide also has to meet the section 503A bulking standards described above.

Sources:

This page is informational. It is not medical advice, it does not recommend any product or dose, and it does not tell you whether any treatment is right for you. Find Peptide Clinics does not sell peptides. Doses and products vary by prescriber and by label, so any treatment question belongs with a licensed clinician.